Press Releases
Jan 19, 2023
PreciseDx Announces Publication in Breast Cancer Research; Validates Its AI-Enabled Platform that Predicts Early-Stage Breast Cancer Recurrence Better than Current Industry Standard
See More
Jan 19, 2023
PreciseDx Announces Publication in Breast Cancer Research; Validates Its AI-Enabled Platform that Predicts Early-Stage Breast Cancer Recurrence Better than Current Industry Standard
See More
Media Coverage
Jan 11, 2023
Demystifying AI's role in healthcare to reassure new providers – and old pros
See More
Jan 11, 2023
Demystifying AI's role in healthcare to reassure new providers – and old pros
See More
Publications
Dec 21, 2022
Development and Validation of an AI-Enabled Digital Breast Cancer Assay to Predict Early-Stage Breast Cancer Recurrence Within 6 Years
See More
Dec 21, 2022
Development and Validation of an AI-Enabled Digital Breast Cancer Assay to Predict Early-Stage Breast Cancer Recurrence Within 6 Years
See More
Media Coverage
Dec 8, 2022
Predictions Series 2022: AiThority Interview with Dr. Jack Zeineh, Co-Founder and CTO at PreciseDx
See More
Dec 8, 2022
Predictions Series 2022: AiThority Interview with Dr. Jack Zeineh, Co-Founder and CTO at PreciseDx
See More
Media Coverage
Jun 15, 2022
How Digital Pathology is Advancing Biomarker Identification & Drug Discovery
See More
Jun 15, 2022
How Digital Pathology is Advancing Biomarker Identification & Drug Discovery
See More
Mar 15, 2022
PreciseDx Appoints Life Science Experts, Molly Harper and Eric Converse, to Board of Directors
See More
Mar 15, 2022
PreciseDx Appoints Life Science Experts, Molly Harper and Eric Converse, to Board of Directors
See More
Media Coverage
Jan 31, 2022
Health Tech: Wayne Brinster On How PreciseDx Technology Can Make An Important Impact On Our Overall Wellness
See More
Jan 31, 2022
Health Tech: Wayne Brinster On How PreciseDx Technology Can Make An Important Impact On Our Overall Wellness
See More
Jan 11, 2022
PreciseDx Raises $10.75 Million Series A Preferred from Healthcare Industry Leaders to Commercialize Cancer Risk Stratification Services to Support Better Patient Insights and Outcomes
See More
Jan 11, 2022
PreciseDx Raises $10.75 Million Series A Preferred from Healthcare Industry Leaders to Commercialize Cancer Risk Stratification Services to Support Better Patient Insights and Outcomes
See More
Dec 10, 2020
PreciseDx Accurately Classifies Low-Risk Recurrence Scores in Breast Cancer
See More
Dec 10, 2020
PreciseDx Accurately Classifies Low-Risk Recurrence Scores in Breast Cancer
See More
Posters & Abstracts
Dec 10, 2019
San Antonio Breast Symposium-19: Development of Novel Automated Grade and Survival Prediction of Breast Cancer Patients Using Machine Learning and AI Algorithms Applied to H&E Images in TCGA Dataset.
See More
Dec 10, 2019
San Antonio Breast Symposium-19: Development of Novel Automated Grade and Survival Prediction of Breast Cancer Patients Using Machine Learning and AI Algorithms Applied to H&E Images in TCGA Dataset.
See More
No results.
Contact us today to learn more about PreciseBreast.
